Jon Cuthbert

The Commodity Futures Trading Commission (CFTC) appointed Donald Battle, an adviser to the Securities and Exchange Commission (SEC) crypto task force, as its new chief data innovation officer.

Qube (ASX:QUB) has delayed its $11.7 billion Macquarie takeover court hearing to July 7 while awaiting key regulatory approvals.

TuHURA Biosciences (NASDAQ:HURA) announced today that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to advance its TBS-2025 therapy.

Coda Octopus Group (NASDAQ:CODA) reported its fiscal second-quarter 2026 financial results for the period ended April 30, 2026.

Context Therapeutics (NASDAQ:CNTX) revealed encouraging preliminary clinical data from its Phase 1a trial evaluating CTIM-76, an investigational bispecific T cell engager designed to target claudin 6 (CLDN6) and engage CD3 T cells.

IDEAYA Biosciences (NASDAQ:IDYA) enrolled the first patient in its Phase 1/2 clinical trial evaluating the combination of its drug candidates, IDE892 and IDE397, in patients with MTAP-deleted solid tumors.

Magnera (NYSE:MAGN) executed an agreement to sell 100 percent of its shares in the Caerphilly, United Kingdom manufacturing operations to Polyart Group.

Wealth management firm AMP (ASX:AMP) has finalised its $150 million on-market share buyback.

Mitsubishi UFJ Financial Group is partnering with Japan’s two other major banks to launch a yen-backed stablecoin by March 2027, marking one of the country's most significant banking-sector blockchain initiatives.

NoviqTech (ASX:NVQ) executed a binding term sheet with Renaissance Group to completely divest its wholly owned subsidiary.